Investment
Features
FeesSafety
Academy
More
Pluang+

Compare The Vita Coco Company Inc (COCO) vs Moderna, Inc. (MRNA) Price & Performance

The Vita Coco Company IncTrade
Moderna, Inc.Trade

Price performance (Past 24H)

Key statistics

The Vita Coco Company Inc vs Moderna, Inc. — how do they compare? The Vita Coco Company Inc trades at $64.43 (market cap $3.63B), while Moderna, Inc. trades at $60.62 (market cap $23.88B). The key difference: Moderna, Inc. is far larger — about 6.6× The Vita Coco Company Inc's market cap. Which is the better fit depends on your goals.

COCOMRNA
Market Cap
$3.63B$23.88B
Sector
TechnologyHealth
52-Week High
$84.02$81.80
52-Week Low
$32.37$22.36
Enterprise Value
$3.37B$20.03B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

The Vita Coco Company Inc

The Vita Coco Company (COCO) trades at $62.25, down 2.92% over 24 hours, with a bullish technical signal driven by oversold RSI readings and support near $62. Fundamentally, Q2 2026 earnings beat expectations with EPS of $0.82 versus $0.56 estimated, while revenue grew 28% year-over-year to $216 million. The company raised full-year 2026 guidance, reflecting strong demand and the Copra acquisition.

Outlook remains positive with 60% analyst buy ratings and an $80.67 consensus price target, implying ~30% upside. Key risks include margin pressure from rising costs and capacity constraints. Growth catalysts include international expansion and health-focused innovation in the beverage sector.

Moderna, Inc.

Moderna (MRNA) stock trades at $59.17, up 9.86% recently, with a bullish technical signal and strong institutional buying interest. The company's Q2 2026 earnings beat expectations, and the FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50+ marks a key post-pandemic milestone. However, fundamentals show declining revenue from $18.9B in 2022 to $1.9B in 2025 and persistent net losses, with a negative net income margin of -142.58% in 2025.

The outlook hinges on pipeline execution; while new vaccine approvals and cost-cutting efforts offer growth potential, the stock faces risks from high valuation multiples and ongoing profitability challenges. Analyst consensus is cautious with a $54.33 price target below the current price, reflecting mixed sentiment amid transitional phase uncertainties.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About The Vita Coco Company Inc

The Vita Coco Company is a leading functional beverage brand specializing in coconut water. Its portfolio includes its flagship Vita Coco brand, clean energy drinks, and sustainable enhanced water products.

Read more on COCO

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA